SCHEMBL5537017

SCHEMBL5537017

CC(C)(C)OC(=O)N1CCCN(CC2(C)CO2)CC1

nearest known ligand 0.44

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
USP2 O75604 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
MEN1 O00255 3/20 0.43
KMT2A Q03164 3/20 0.43
HPGD P15428 1/20 0.42
CTSK P43235 1/20 0.40
CHRM2 P08172 1/20 0.40
CHRM4 P08173 1/20 0.40
CHRM1 P11229 1/20 0.40
CHRM3 P20309 1/20 0.40
PARP1 P09874 1/20 0.40
MAPT P10636 3/20 0.39
EPHX2 P34913 1/20 0.39
RECQL P46063 1/20 0.37
EPHX1 P07099 1/20 0.37
ALDH1A1 P00352 2/20 0.37
LMNA P02545 1/20 0.37
DDB1 Q16531 1/20 0.37
CRBN Q96SW2 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6010940 0.94 USP2 (0.49) USP2SMN1; SMN2MEN1KMT2AHPGD
SCHEMBL6010726 0.94 USP2 (0.49) USP2SMN1; SMN2MEN1KMT2AHPGD
SCHEMBL5539680 0.94 USP2 (0.49) USP2SMN1; SMN2MEN1KMT2AHPGD
SCHEMBL5540211 0.81 USP2 (0.46) USP2SMN1; SMN2HPGDCHRM2CHRM4
SCHEMBL5539461 0.79 CHRM2 (0.50) USP2SMN1; SMN2MEN1KMT2AHPGD
SCHEMBL2904258 0.78 MEN1 (0.50) USP2SMN1; SMN2MEN1KMT2AHPGD
SCHEMBL16612394 0.77 USP2 (0.62) USP2SMN1; SMN2MEN1KMT2AHPGD
SCHEMBL10246569 0.76 CHRM2 (0.48) USP2SMN1; SMN2MEN1KMT2AHPGD
SCHEMBL1920985 0.76 MEN1 (0.48) USP2SMN1; SMN2MEN1KMT2AHPGD
SCHEMBL17606853 0.75 MEN1 (0.41) USP2SMN1; SMN2MEN1KMT2AHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2570418-A2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-03-20 EP disclosed
EP-1555267-B1 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES OTSUKA PHARMA CO LTD (JP) 2013-01-16 EP disclosed
US-7262212-B2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-28 US disclosed
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-05-04 US disclosed
EP-1555267-A1 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2005-07-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles NR2C2, NR4A3, NR4A2 USP2 3074/4885SMN1; SMN2 3985/4885MEN1 3295/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.